Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
Objective: This paper presents the final analysis of once-daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment-naïve HIV-1-infected adults. Methods: ARTEMIS (AntiRetroviral Therapy with TMC114 ExaMined In naïve Subjects; NCT00258557) was a randomized, open-label, phase-III,...
Saved in:
Main Authors: | C. Orkin, E. Dejesus, H. Khanlou, A. Stoehr, K. Supparatpinyo, E. Lathouwers, E. Lefebvre, M. Opsomer, T. Van de Casteele, F. Tomaka |
---|---|
Format: | Journal |
Published: |
2018
|
Subjects: | |
Online Access: | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84870533547&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/52951 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial
by: C. Orkin, et al.
Published: (2018) -
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
by: Foca M., et al.
Published: (2017) -
Rilpivirine pharmacokinetics without and with darunavir/ritonavir once daily in adolescents and young adults
by: Marc Foca, et al.
Published: (2018) -
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
by: Kulkanya Chokephaibulkit, et al.
Published: (2018) -
Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: Comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir
by: Chokephaibulkit K., et al.
Published: (2014)